Effects of insulin glulisine as mono- or add-on therapy in patients with type 2 diabetes mellitus

Diabetes, Obesity and Metabolism

Volumn 11, Issue 9, 2009, Pages 900-909

  Kawamori, Ryuzo ^a   Iwamoto, Y ^b   Kadowaki, T ^c   Iwasaki, M ^d   Kim, S W ^e   Woo, J T ^f   Baik, S H ^g   Yoon, K H ^h  

^a JUNTENDO UNIVERSITY   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d SEIKEI UNIVERSITY   (Japan)

^e Sungkyunkwan University School of Medicine   (South Korea)

^f Kyung Hee University College of Medicine   (South Korea)

^g Korea University College of Medicine   (South Korea)

^h The Catholic University of Korea   (South Korea)

Author keywords

Insulin glulisine; Type 2 diabetes

Indexed keywords

BIGUANIDE; CARBOHYDRATE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN GLULISINE; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

ADD ON THERAPY; ADULT; ARTICLE; BENIGN TUMOR; BODY MASS; BODY WEIGHT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC COMA; DIABETIC RETINOPATHY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INJURY; INSULIN DEPENDENT DIABETES MELLITUS; INTOXICATION; KIDNEY DISEASE; MALE; MALIGNANT NEOPLASTIC DISEASE; METABOLIC DISORDER; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NEUROLOGIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL DISORDER; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT DISEASE;

AGED; BIGUANIDES; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS, SUBCUTANEOUS; INSULIN; MALE; MIDDLE AGED; SULFONYLUREA COMPOUNDS;

EID: 69249215409     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/j.1463-1326.2009.01088.x     Document Type: Article

References (26)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression on long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
2. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in subjects with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853 (Erratum in: Lancet 1999; 354: 602).
3. Chehade JM, Mooradian AD. A rational approach to drug therapy of type 2 diabetes mellitus. Drugs 2000; 60: 95-113.
4. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-372.
5. Turner RC, Cull CA, Frighi V, Holman RR, for the UK Prospective Diabetes Study (UKPDS) Group. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA 1999; 281: 2005-2012.
6. Harris MI, Eastman RC, Cowie CC, Flegal KM, Eberhardt MS. Racial and ethnic differences in glycemic control of adults with type 2 diabetes. Diabetes Care 1999; 22: 403-408.
7. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997; 20: 1183-1197.
8. Yki-Jarvinen H. Role of insulin resistance in the pathogenesis of NIDDM. Diabetologia 1995; 38: 1378-1388.
9. Heinemann L, Heise T, Jorgensen LN, Starke AA. Action profile of the rapid acting insulin analogue: Human insulin B28Asp. Diabet Med 1993; 10: 535-539.
10. Rave K, Klein O, Frick AD, Becker RH. Advantage of premeal-injected insulin glulisine compared with regular human insulin in subjects with type 1 diabetes. Diabetes Care 2006; 29: 1812-1817.
11. Becker RH. Insulin glulisine complementing basal insulins: A review of structure and activity. Diabetes Technol Ther 2007; 9: 109-121.
12. Becker RH, Frick AD. Clinical pharmacokinetics and pharmacodynamics of insulin glulisine. Clin Pharmacokinet 2008; 47: 7-20.
13. Kapitza C, Becker R, Frick A, Heise T, Rave K. Pharmacodynamics and pharmacokinetics of insulin glulisine compared with insulin lispro and regular human insulin in patients with type 2 diabetes [abstract 733]. Diabetologia 2004; 47 (Suppl. 1): A265.
14. Dailey G, Rosenstock J, Moses, RG, Ways K. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004; 27: 2363-2368.
15. Min HK. Non-insulin-dependent diabetes mellitus (NIDDM) in Korea. Diabet Med 1996; 13 (Suppl. 6): S13-S15.
16. Kim DJ, Song KE, Park JW, Cho HK, Lee KW, Huh KB. Clinical characteristics of Korean type 2 diabetic patients in 2005. Diabetes Res Clin Pract 2007; 77 (Suppl. 1): S252-257.
17. Seino Y. New concept of diabetes mellitus. Med Frontline 1995; 50: 639-645.
18. Ishida T. Insulin resistance and liver. Nippon Rinsho 2000; 58: 348-356.
19. Matsumoto K, Miyake S, Yano M et al. Glucose tolerance, insulin secretion, and insulin sensitivity in non-obese and obese Japanese subjects. Diabetes Care 1997; 20: 1562-1568.
20. Riddle MC, Rosenstock J, Gerich J, for the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003; 26: 3080-3086.
21. Leiter LA, Ceriello A, Davidson JA et al. Postprandial glucose regulation: New data and new implications. Clin Ther 2005; 27 (Suppl. B): S42-S56.
22. 1c. Diabetes Care 2003; 26: 881-885.
23. DECODE Study Group, on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality: Comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 2001; 161: 397-405.
24. Home P. Contributions of basal and post-prandial hyperglycaemia to micro- and macrovascular complications in people with type 2 diabetes. Curr Med Res Opin 2005; 21: 989-998.
25. Araki E, Iwamoto Y, Kadowaki T et al. Treatment Guide for Diabetes. Japanese Diabetes Society, ed. Tokyo, Japan: Bunkodo Co., Ltd; 2008; [in Japanese].
26. Kawamori R, Eliaschewitz FG, Takayama H, Hayashida CY. Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 79: 97-102.